Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2006

View Archived Issues

Aerosolized hydroxychloroquine studied in phase II for asthma

Bayer concludes divestment of antiinfectives research to Santo Holding

Orphan drug designation for SLIT Amikacin

American businesses of Sankyo and Daiichi to integrate

Immtech International changes name to Immtech Pharmaceuticals

Vertex and CFFT form new collaboration to develop VX-770 for cystic fibrosis

Samaritan concluding preclinical studies of SP-233 for Alzheimer's disease

Allergan completes acquisition of Inamed

Enrollment completed in phase III study of TH-9507 for HIV lipodystrophy

Phase III hepatorenal syndrome study of terlipressin completes enrollment

Schering AG supports Bayer offer

FDA Advisory Committee recommends against approval of Sparlon for ADHD

TBC-3711 on clinical hold following rat finding

Phase I/II study evaluates nimotuzumab for NSCLC

Idenix modifies phase IIb trials of valopicitabine

Phase II findings for ACP-103 for treatment-induced psychosis in Parkinson's

Orphan drug designation for Aastrom's Tissue Repair Cells in osteonecrosis

Spectrum to acquire oncology drug assets of Targent

Ranexa now available for chronic angina

Approvable letter for Thelin in PAH

In vivo efficacy of a novel CCR3 antagonist for allergic inflammatory disease

Avidex reports new immunomodulatory agents

Recent patents report new therapeutic agents for metabolic disorders

BMS-355249: novel potentiator of NT-3-mediated trk A and trk B activation

Novel LFA-1 antagonist demonstrates biological activity in vivo

Dipyridamole analogue potently inhibits ENT1

Spotlight on prostaglandin E2 EP1 receptors as mediators of neurotoxicity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...